

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/36173

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; C07H 21/04; A61K 48/00 US CL : 435/6; 536/24.5; 514/44 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6; 536/24.5; 514/44 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DIALOG, MEDLINE, WEST		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Tsuji et al. Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial Cells, Biochemical and Biophysical Research Communications, 1998, Vol. 245, pages 583-588.	1, 3, 4, 8-15, 17, 18 and 22-24
A	Bierhaus et al. Advanced Glycation End Product (AGE)-- Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE, Circulation, 1997, Vol. 96, pages 2262-2271.	1, 3-6, 9-15, 17-20 and 23-24
Y	Sajithlal et al. Receptor for Advanced Glycation End Products Plays a More Important Role in Cellular Survival than in Neurite Outgrowth during Retinoic Acid-induced Differentiation of Neuroblastoma Cells, The Journal of Biological Chemistry, 2002, Vol. 277, No. 9, pages 6888-6897.	1, 3, 4, 6, 9-15, 17, 18, 20
Y	Yan et al. RAGE and amyloid-B peptide neurotoxicity in Alzheimer's Disease, Nature, August 1996, Vol. 382, pages 685-691.	1, 3, 4, 5, 9-15 and 17-19
P, Y	U.S. 6,506,559 B1 (FIRE et al) 14 January 2003 (14.01.2003), see entire document.	1, 3, 4, 7, 9-15, 17, 18 and 21
A	US 2003/0013699 A1 (DAVIS et al) 16 January 2003 (16.01.2003), see entire document.	1 and 15
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 14 March 2005 (14.03.2005)		Date of mailing of the international search report 07 APR 2005
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer <i>Jamuleh Bowman</i> Amy H. Bowman Telephone No. (571)272-0755

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/36173

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, 2000, 18:307-319.	1-22
T	Branch, A good antisense molecule is hard to find, TIBS, February 1998, pp 45-50.	1-22
T	Green et al., Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, J Am Coll Surg, July 2000, Vol. 191, No. 1, pp 93-105.	1-22
T	Fire, RNA-triggered gene silencing, September 1999, TIG, Vol. 15, No. 9, pages 358-363.	1-22
T	Caplen et al., dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference, 2000, Gene, pages 95-105.	1-22
T	Fire et al., Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis elegans, February 1998, Nature, Vol. 391, pages 806-811.	1-22
A	Lue et al., Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiology of Aging, 2001, pages 945-956.	1-22
Y	Carmeliet et al. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovascular Research, 1998, Vol. 39, pages 8-33.	1-22